Not only is the global prevalence of Diabetes Mellitus (DM) and Diabetic Retinopathy (DR) expected to increase, but concomitantly the global prevalence of vision-threatening DR (VTDR), which includes diabetic macular edema, severe non-proliferative (NPDR) and proliferative disease (PDR), is also projected to increase. The international number of patients with VTDR is estimated to increase by 57% from 28.5 million in 2020 to 44.8 million in 2045 [1]. Screening to detect early sight-threatening lesions of DR for timely monitoring and treatment is an important strategy to reduce the burden of vision loss due to DR.